platinum has been researched along with Hodgkin Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Behnia, S; Cassaday, RD; Gopal, AK; Graf, SA; Green, DJ; Holmberg, L; Libby, EN; Maloney, DG; Onishi, M; Pagel, JM; Philip, M; Press, OW; Roden, JE; Schiavo, K; Shustov, AR; Smith, SD; Till, BG | 1 |
1 other study(ies) available for platinum and Hodgkin Disease
Article | Year |
---|---|
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Topics: Adolescent; Adult; Brentuximab Vedotin; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Platinum; Positron-Emission Tomography; Prognosis; Treatment Outcome; Young Adult | 2015 |